Multiple Myeloma
Conference Coverage
Distinct toxicity profiles for anti-BCMA myeloma therapies
New FDA data analysis shows CAR T-cell and other anti-BCMA treatments for multiple myeloma are linked to considerable risks for side effects.
Conference Coverage
Myeloma: Isatuximab Four-Drug Regimen Boosts MRD Negativity
Quadruplet regimen with anti-CD38 drug isatuximab improved MRD negativity vs. the standard triplet regimen in newly diagnosed myeloma patients.
Conference Coverage
In real world, patients with myeloma have worse outcomes
Canadian study indicates that real-world outcomes for patients treated for myeloma fall far short of those in clinical trials.
Conference Coverage
ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes
Leaders of the American Society of Hematology preview hot topics and presentations on tap at their 2023 annual meeting.
Feature
Time to stop routine maintenance therapy in myeloma?
Research now suggests some multiple myeloma patients may not need indefinite, costly maintenance therapy after stem cell transplantation.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Feature
Survival on the upswing in myeloma
Hematologists say that median lifespans are reaching 10 years or more after diagnosis.
Conference Coverage
Debate: Should smoldering myeloma be treated?
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
News
FDA approves motixafortide for stem cell mobilization in myeloma
Motixafortide has been approved by the FDA to help mobilize hematopoietic stem cells in autologous transplants for patients with multiple myeloma...